Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Buys 3,802 Shares of Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 3,802 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $24.97 per share, with a total value of $94,935.94. Following the acquisition, the insider owned 6,375,972 shares of the company’s stock, valued at approximately $159,208,020.84. This represents a 0.06% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, May 20th, Ra Capital Management, L.P. acquired 996 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.94 per share, with a total value of $24,840.24.
• On Tuesday, May 12th, Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.90 per share, with a total value of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.46 per share, with a total value of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Trading Down 0.6%

NASDAQ COAG traded down $0.17 on Thursday, hitting $26.30. 193,388 shares of the company were exchanged, compared to its average volume of 251,804. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.